In the ever-growing world of MedTech, HeartFlow fills a distinct niche: its technology aims to improve the efficacy with which coronary artery disease is detected, treated, and prevented. HeartFlow’s technology is available in the U.S. and internationally, and the company reports a high degree of success in diagnosing this disease, a major cause of death worldwide. The company claims more than a quarter of a million patients and adoption of its technologies in more than 750 hospitals. Its latest product, HeartFlow ONE, provides comprehensive imaging for coronary artery disease diagnostics, also known as a CCTA scan. This is a crucial step in diagnosing issues of heart health, and is entirely noninvasive, with a much higher success rate than more traditional diagnostic methods.